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The Ras-ERK and PI3K-mTOR pathways are hyperactivated in various malignant tumors. 
Feedforward (FF) and feedback (FB) regulations between the Ras-ERK and the PI3K-
mTOR pathways have been suggested to attenuate sensitivity to drugs targeting to these 
pathways and confer tumors resistance to therapies. However, because analyses of such 
regulations require measurements and perturbations with high temporal resolution, the 
quantitative roles played by FF and FB regulations in the intrinsic resistance to molecular 
targeting drugs remain still unclear. To address this issue, we quantified FF and FB 
regulations of the EGFR signaling pathway by FRET imaging. EGF-induced activation of 
EGFR, Ras, ERK, and S6K with or without inhibitors was measured by FRET imaging, and 
analyzed by semi-automatic image processing. Based on the imaging data set and kinetic 
parameters determined by our previous studies, we identified the roles played by a coherent 
FF regulation and two negative FB regulations, one of which was not recognized 
previously. The systems analyses revealed how these FF and FB regulations shape the 
temporal dynamics of ERK activity upon EGF stimulation. Furthermore, the simulation 
model predicts the response of molecular targeting drugs applied solely or in combination 
with each other to BRaf- or KRas-mutated cancer cell lines, indicating the validity of 








The Ras-Raf-MEK-ERK MAP kinase cascade (hereinafter referred to as the Ras-ERK 
pathway) is an essential signal transduction pathway for proliferation and differentiation [1, 
2], while the PI3K-Akt-mTORC1-S6K signaling pathway (hereinafter referred to as the 
PI3K-S6K pathway) plays pivotal roles in the process of apoptosis and survival [3]. 
Importantly, the deregulation of these signaling pathways through processes such as gene 
mutation and amplification induces tumorigenesis [4]. Therefore, molecules in these 
pathways are potential targets for cancer therapy. Several drugs targeting the Ras-ERK or 
the PI3K-S6K pathway, including MEK inhibitors, Raf inhibitors, and PI3K inhibitors, are 
  
currently under clinical evaluations. However, the anti-cancer effects of these drugs varied 
significantly among cancer cells harboring different combinations of gene mutations, so 
that it is remarkably difficult to predict the drug response of individual cancers [5]. This 
problem is largely due to the complexity of the signaling networks controlling cancer cells 
[6], which makes it difficult to predict the effect of each molecular targeting drug on the 
total dynamics of the signaling pathways. 
 Complexity in signaling pathways arises from feedforward (FF) and feedback (FB) 
regulations and cross-talk among signaling pathways [7]. Previous studies had revealed the 
existence of various FB and cross-talk regulations in the Ras-ERK and PI3K-S6K pathways 
[8-12]. It has been suggested that FB regulations neutralized drug efficiency in tumor cells, 
a phenomenon known as intrinsic resistance [13-15]. Many of the previous studies have 
focused on the individual roles played by separate FB regulations. Cirit et al. contributed an 
elegant systematic quantification of negative FB mechanisms by data-driven modeling with 
biochemical data and global parameter fitting in PDGF-induced ERK activation [16]. They 
employed the expression of dominant negative mutants or pretreatment of chemical 
inhibitors to identify the negative FB in a simulation model. More recently, FF and FB 
regulations in the EGFR signaling network were quantified by modular response analysis 
[17]. However, a time-lapse measurement system combined with acute perturbations that 
were faster than the FB time scale has been direct method to distinguish whether a 
signaling component was merely required for a signaling pathway or whether it functioned 
as part of the FB loop [18].  
 In this study, we attempted to quantitatively evaluate FF and FB regulations in the 
Ras-ERK and PI3K-S6K pathways induced by epidermal growth factor (EGF). To this end, 
we employed biosensors based on the principle of Förster/fluorescence resonance energy 
transfer (FRET) [19] and chemical inhibitors to quickly perturb the activity of signaling 
molecules. Based on these data, we found one FF and two FB regulations that functioned in 
a coordinated fashion in the ERK activity dynamics induced by EGF stimulation. In 
addition, this model predicted the effect of molecular targeting drugs on the cell 





Time-lapse FRET imaging in the Ras-ERK and the PI3K-S6K pathways 
  
To quantitatively measure the temporal dynamics of the Ras-ERK and the PI3K-S6K 
pathways, we developed HeLa cell lines stably-expressing FRET biosensors for EGFR 
(PicchuEV-pm), Ras (RaichuEV-Ras), ERK (EKAREV-nuc), JNK (JNKAREV-nuc), PKA 
(AKAR3EV), or S6K (Eevee-S6K) [20] (Fig. 1, left). Three cell lines expressing FRET 
biosensors in the nucleus (ERK or JNK), cytoplasm (S6K or PKA), and plasma membrane 
(EGFR or Ras) were co-cultured in a 96-well or 4-well glass-bottom dish. In this way, we 
could monitor the activities of the three signaling molecules simultaneously, which 
improved the throughput of the data acquisition. To extract FF and FB regulations, we 
perturbed the signaling pathways acutely by adding chemical inhibitors. In this study, we 
applied 10 or 50 ng/ml EGF stimulation, which could maximally activate the downstream 
signaling pathways in HeLa cells [21]. The time-lapse images were semi-automatically 
processed to calculate FRET/CFP values representing the activities of molecules (Fig. 1, 
center). Finally, the quantified time-lapse data were applied to build the kinetic simulation 
model (Fig. 1, right). These results provided large-scale time-course data of the changes in 
EGFR, Ras, ERK, JNK, PKA and S6K activity upon EGF stimulation in combination with 
chemical inhibitors (Supplementary dataset 1). In this study, we do not utilize the data on 
JNK and PKA, because in the time-frame of the current study we could not find any 
substantial cross-talk between JNK or PKA and the Ras-ERK or PI3K-S6K pathways. 
These FRET biosensors appeared to linearly monitor endogenous activity of interest, except 
for EGFR and ERK biosensor, PicchuEV-pm and EKAREV-nuc, respectively. These two 
highly-sensitive FRET biosensors are saturated upon EGF stimulation (Fig. 2A and 2B) and 
could not monitor the decrease of phosphorylation of ERK and EGFR, which was detected 
previously by Western blotting [21]. To overcome this problem, we calibrated FRET/CFP 
values of EKAREV-nuc with the amount of phosphorylated ERK (Fig. 2C and 2D). By this 
way, the FRET/CFP ratio of EKAREV-nls were translated into the level of phospho-ERK 
and used to fit the simulation data with the experimental data (see below). We did not apply 
this approach to the other biosensors, which did not show saturation of the signals.  
 During the course of these analyses, we found the following two FB regulations 
and one coherent FF regulation in the Ras-ERK and the PI3K-S6K pathways: the negative 
FB regulation from ERK to EGFR [22], the positive FF regulation from Ras to Raf through 
PI3K and Rac1 [11], and the negative FB from RSK to Raf through TSC and Rheb [9, 10]. 
 
A negative feedback loop from ERK to EGFR 
First, we noticed the FB regulation of ERK to EGFR (Fig. 3A). When EGF-stimulated cells 
  
were treated with an MEK inhibitor, PD184352, EGFR activity was significantly increased 
as monitored by PicchuEV-pm (Fig. 3B, left, green line). In cells preincubated with 
PD184352 before EGF stimulation, the decrease in EGFR activity was slower than in 
untreated cells or cells preincubated with a PI3K inhibitor, LY-294002, or an EGFR 
inhibitor, PD153035 (Fig. 3B, right, green line). These results provided evidence of the 
negative FB regulation from ERK to EGFR and agreed with previous reports that EGFR 
are negatively regulated by the ERK-mediated phosphorylation of Thr-669 [22]. 
 
A coherent feedforward regulation from Ras to Raf through PI3K and Rac 
Second, we observed the FF regulation of PI3K to ERK (Fig. 3C). When EGF-stimulated 
cells were treated with a PI3K inhibitor, PI-103, ERK was inhibited transiently in the early 
phase (<10 min), followed by partial recovery in the later phase (>20 min) (Fig. 3D, red 
line). It has been reported that PI3K activates Raf and thereby ERK1/2 in a Rac1- and PAK-
dependent manner [11]. In agreement with this report, expression of a Rac1 dominant 
negative mutant markedly reduced the EGF-induced ERK activation (Fig. 3E). 
Furthermore, Ras dominant negative mutant almost completely abrogated EGF-induced 
S6K activation (Fig. 3F), showing that Ras activity was required for PI3K activation in 
EGF-stimulated HeLa cells [23].   
 
A negative feedback loop from RSK to Raf through TSC and Rheb 
Third, we found that RSK negatively regulated the ERK pathway by regulating the TSC-
Rheb pathway (Fig. 3G). As reported previously [24], the RSK inhibitor BI-D1870 induced 
ERK activation, implicating RSK in the negative FB regulation of ERK (Fig. 3H). We 
considered the following scheme: RSK1 phosphorylates TSC2 at Ser-1798 to inhibit GAP 
activity of the TSC1/TSC2 complex, and thereby activates Rheb [9]. Activated Rheb in turn 
binds to and inhibits BRaf [10]. In further support of the negative FB model, pretreatment 
with the RSK inhibitor attenuated EGF-induced S6K activation (Fig. 3I, green line). The 
involvement of Rheb was examined by reducing the amount of Rheb by knockdown. 
Addition of a low-dose RSK inhibitor, wherein ERK could be activated only slightly in 
control cells, activated ERK markedly in the Rheb-knockdown cells (Fig. 3J). On the other 
hand, Torin1, an mTORC1/2 inhibitor, did not affect ERK activity, excluding mTOR from 
the negative FB (Fig. 3G-I).  
 
A kinetic simulation model made up of the Ras-ERK and the PI3K-S6K pathways and FF 
  
and FB regulations 
To understand the coordinated effects of FF and FB regulations on the Ras-ERK and the 
PI3K-S6K pathways, we employed a systems biology approach. That is, we used a 
simulation model of the EGFR-Ras-ERK pathway with as many experimentally determined 
kinetic parameters as possible. More than 30 kinetic parameters in this signaling pathway 
have been determined in previous studies (Tables S1-S2) [8, 21]. In the present study, we 
introduced the signaling molecules belonging to the PI3K-S6K pathway and included the 
aforementioned FF and FB regulations (Fig. 4). Kinetic parameters in the PI3K-S6K 
pathway were estimated by fitting numerical simulation with experimental data (Tables S1-
S2). Since EKAREV-nuc had high sensitivity, the amount of phosphorylated ERK 
calculated in simulation was converted into FRET/CFP values in EKAREV-nuc for 
parameter fitting (Fig. 5). The simulation overall reproduced the experimental data set, 
despite there were substantial discrepancies (see Discussion).  
 The model comprising the Ras-ERK and PI3K-ERK pathways could capture key 
dynamics of the experimental observations (Fig. 6A). For instance, MEK inhibition 
reactivated EGFR (Fig. 6B, left), and PI3K inhibition transiently inactivated ERK (Fig. 6B, 
right) as observed in the experiment (Fig. 3B and 3D, respectively). Further, the cross-talk 
between the Ras-ERK and PI3K pathways was evidenced by the effect of inhibition of 
Rac1 and Ras (Fig. 6C, D). The ERK activation and S6K inhibition by the RSK inhibition 
shown in Fig. 3H and 3I were also generally reproduced (Fig. 6E). Finally, the ERK 
activation by the RSK inhibitor in cells deficient in Rheb was also reproduced (Fig. 6F).  
 
Computational and experimental demonstration of the roles played by cross-talk, FB 
regulation, and FF regulation.  
The versatility of the simulation model could be demonstrated by predicting phenomena 
that might not be forecast intuitively. In the simulation model, MEK inhibition of EGF-
stimulated cells caused a rapid but slight inhibition of S6K activity, followed by gradual 
increase (Fig. 7A, green line). Meanwhile, PI3K inhibition induced a marked inhibition of 
S6K, followed by slight recovery (Fig. 7A, red line). These adaptation-like behaviors 
suggested that the FF and FB regulations exerted coordinated effects on the Ras-ERK and 
PI3K-S6K pathways [25]. We examined the effects of the MEK and PI3K inhibitors 
experimentally (Fig. 7B). Expectedly, those adaptation-like behaviors predicted by the 
simulation were reproduced constantly. Furtheremore, we predicted that RSK inhibition 
would reduce EGF-induced Ras activation (Fig. 7C), because RSK inhibition cancels the 
  
negative FB from RSK to Raf, and thereby upregulates the negative FB from ERK to Sos1. 
The prediction was validated experimentally (Fig. 7D): Preincubation with RSK inhibitor 
strongly suppressed EGF-induced Ras activation.  
 Next, we directly examined the contribution of the individual FF and FB 
regulations to the dynamics of ERK activation by abrogating each of them in silico (Fig. 
7E, 7F). First, shut-off of RSK inhibition of TSC increased basal ERK activity, showing the 
central role of the negative FB regulation from RSK to Raf in controlling the ERK activity 
before EGF stimulation (Fig. 7E and 7F, left). Second, shut-off of PI3K-Rasc-Raf FF 
regulation strongly suppressed EGF-induced ERK activation, especially in the early phase 
(~ 10 min), indicating the large contribution of the PI3K-Rac-Raf pathway to the EGF-
induced ERK activation (Fig. 7E and 7F, center). Third, shut-off of the negative FB 
regulation from ERK to EGFR/Sos1 caused sustained ERK activation after EGF 
stimulation (> 10 min) (Fig. 7E and 7F, right).  
 
Prediction of the effect of molecular targeting drugs on cancer cell growth 
We attempted to apply the simulation model to predict the effect of molecular targeting 
drugs on the growth of BRaf- or KRas-mutated cancer cell lines. As the source of 
experimental data, we employed pharmacological profiling data obtained from the Cancer 
Cell Line Encyclopedia (CCLE), which catalogues the dose-response data for 24 anticancer 
drugs across 479 cancer cell lines [5]. The dose-response data for MEK and BRaf inhibitors 
were extracted and averaged from BRaf-mutated cell lines and KRas-mutated cell lines 
(Fig. 8A, B). The BRaf-mutated cell lines were sensitive to a BRaf inhibitor, PLX-4720, 
and an MEK inhibitor, AZD6244; whereas the KRas-mutated cell lines were resistant to the 
BRaf inhibitor and less sensitive to the MEK inhibitor than the BRaf-mutated cell lines 
(Fig. 8A). This result was consistent with the analysis using different data set from other 
groups (Supplementary dataset 2) [26]. Further, we collected data on the effect of the PI3K 
inhibitor, PI-103, and the combination of the MEK inhibitor and PI3K inhibitor in a KRas-
mutated cell line, HCT-116, and a BRaf-mutated cell line, HT-29 (Fig. 8B). Intriguingly, 
HCT-116 cells showed higher sensitivity to the PI3K inhibitor than did HT-29 cells (Fig. 
8B, left). The combination of MEK and PI3K inhibitors efficiently inhibited the cell growth 
of both HCT-116 and HT-29 cells (Fig. 8B, right).  
 To simulate these pharmacological data, a KRas or BRaf mutation was first 
introduced into the simulation model (Fig. 4 and Table S1). The problem here was that the 
simulation model provided dose-response effects of molecular targeting drugs on the 
  
activities of signaling molecules, but not on the cell survival and proliferation provided by 
the source data. Thus, to accommodate the experimental observations to the simulation 
model, we tried to identify a parameter that correlated with the cytotoxicity in experimental 
data. Eventually, we found that the sum of the fraction of phosphorylated ERK (pERK) and 
phosphorylated Akt (pAkt) correlated highly with the cell growth data (Fig. 8C). Thus, the 
sum of pERK and pAkt may serve as a useful index to predict the effects of molecular 
targeting drugs on the cell growth in KRas- and BRaf-mutated cells. 
 Lastly, we used the simulation model to investigate the involvement of the FF and 
FB regulations in the differential response between the BRaf-mutated cells and KRas-
mutated cells. The results in the KRas-mutated cells demonstrated that both ERK and Akt 
were substantially phosphorylated in these cells (Fig. 9A). The partial resistance to MEK 
inhibitor was due to the further activation of Akt by MEK inhibition through the inhibition 
of negative FB from ERK to EGFR (Fig. 9A, right, blue line). Meanwhile, BRaf-mutated 
cells indeed showed the increase in pAkt in the presence of MEK inhibitor (Fig. 9B). 
However, the absolute value of the increase in pAkt was only 2% of total Akt (Fig. 9B, 
right, inset), and therefore these cells were almost exclusively dependent on ERK 
pathways. Taken together, these results provide quantitative insight into useful treatments in 
KRas- and BRaf-mutated cells by taking the FF and FB regulations into account (Fig. 9C). 
KRas-mutated cells should be treated with the combination of both MEK and PI3K 






The roles played by FF and FB regulations in the Ras-ERK pathway have been studied by 
several research groups using different approaches. Santos et al. applied modular response 
analysis (MRA) to unveil the role of the Ras-ERK pathway in the neuronal differentiation 
of PC12 cells. They found that, upon EGF stimulation, the network exhibits negative 
feedback only, whereas upon NGF stimulation a positive feedback also appears and induces 
neuronal differentiation by bi-stable Erk activation [27]. Klinger et al. also adopted MRA in 
order to predict potent combinatorial treatments by inhibitors targeting the Ras-ERK and 
the PI3K-AKT pathways [17]. The MRA approach can handle a huge number of readouts 
and perturbations by high-throughput methods, which the ODE-based approach cannot. In 
  
comparison to the ODE-based model used in the present study, Klinger’s model includes 
negative FB regulation from ERK to EGFR and ERK to Raf, but lacks FF regulation from 
PI3K to Raf and negative FB regulation from RSK to Raf. The MRA approach draws the 
network structure primarily based on previous studies; therefore, the MRA-based model 
infers the contribution of each module, but cannot discover regulations that were not known 
or predicted previously. Furthermore, MRA relies on linear approximation under a system 
in the steady state, rendering it difficult to identify regulations that involve non-linear 
systems, such as complete adaptation, by this system.  
On the other hand, the ODE-based approach is simple but heuristic. In fact, we 
were able to discover previously-unknown pathways, such as FB regulation from RSK to 
Raf, using this method. Cirit et al. also adopted the ODE-based approach, and were able to 
infer that negative regulation of MEK kinase plays a dominant role in the self-regulation of 
ERK activity in mouse fibroblasts [16]. Cirit’s ODE-based approach is similar to our 
approach, i.e., data-driven modeling. In comparison to Cirit's model, our ODE model lacks 
negative FB regulation from ERK to Raf (Fig. 7F). Because FB from ERK to Raf 
complements FB from ERK to Sos1, in Cirit’s model the FB regulation from ERK to Sos1 
contributes to the suppression of ERK activity significantly less than in our model. The 
reason for this difference will only be clarified by experimentally accounting for all the 
actual parameters affecting these two FBs. Thus, we concluded that time-lapse data of 
many readouts with high temporal resolution and acute perturbations are essential to 
understand the effect of FF and FB regulation as an integral system of signaling pathway. 
Multiple mechanisms of resistance to MEK inhibitors, such as acquired and 
intrinsic resistance, have been proposed [28-31]. The present study examined the role of the 
quantitative simulation model in the prediction of intrinsic resistance to molecular targeting 
drugs in cancer cells. Our data are consistent with the previous studies: BRaf-mutated cells 
showed higher sensitivity to an MEK inhibitor than KRas-mutated cells [32] (Fig. 8A), an 
MEK inhibitor caused PI3K activation through the release of negative FB from ERK [12] 
(Fig. 9A and 9B), and the combination of an MEK inhibitor with a PI3K inhibitor was a 
rational treatment for KRas mutated cells [33] (Fig. 8B and 8C). In the present work, we 
further proposed a mechanistic explanation for the difference in MEK inhibitor sensitivity 
between KRas- and BRaf-mutated cells; i.e., the strength of PI3K activation induced by 
treatment with an MEK inhibitor. Recent reports have demonstrated an MEK inhibitor-
induced increase in Akt phosphorylation in BRaf-mutated cells, and have suggested the 
combination of MEK and PI3K inhibitors as a rational therapy for BRaf-mutated cells [14, 
  
17]. However, these studies did not quantify phosphorylated Akt, but only showed the fold 
increase of pAkt in the presence and absence of MEK inhibitor. Our simulation model also 
indicated that the MEK inhibitor-induced fold increase in pAkt is much higher in BRaf-
mutated cells than in KRas-mutated cells. Surprisingly, however, the fraction of pAkt was 
much lower than the fraction of pERK in BRaf-mutated cells (Fig. 9A and 9B). Thus, the 
fraction of pAkt did not reach a level sufficient to confer resistance to an MEK inhibitor in 
BRaf-mutated cells. 
It is noteworthy that some FF and FB regulations included in previous models are 
omitted in our simulation model. Although we did not directly examine the effect of such 
FF and FB regulations, the readouts of FRET imaging should comprise the effect of such 
FF and FB regulations. Therefore, the fitted parameters in our model should include the 
effects of the FF and FB regulations that are not explicitly included in our simulation 
model. It will be beneficial to discuss some of the reported FB regulations that are not 
included in our model. First, ERK is known to phosphorylate and inhibit CRaf and MEK, 
serving as a mechanism of negative FB regulations [34, 35]. Our model is already 
implemented two negative FB pathways from ERK to Sos1 and EGFR. The parameters 
used to characterize these two negative FB pathways probably compensate the lack of 
negative FB regulations from ERK to CRaf and MEK. Second, it is reported that not only 
RSK but also ERK phosphorylates and inactivates TSC2 [36]. Again, it is likely that the 
effect of TSC2 inactivation by ERK is included in the parameters used to characterize 
TSC2 inactivation by RSK. Third, a positive FB loop from Ras-GTP to Sos have been 
reported by Gureasko et al [37]. Because we adopted Gureasko’s parameter to describe the 
Sos-dependent Ras activation, our model includes the effect of this positive FB loop, even 
though it is not explicitly drawn in the model. Fourth, Raf kinase inhibitor protein (RKIP) 
is known to be phosphorylated and inactivated by ERK, thereby implementing a positive 
FB loop [38]. This positive FB loop should increase EGF-induced ERK phosphorylation in 
the early phase as does the positive FF from PI3K to Raf (Fig. 7E). Accordingly, the effect 
of the positive FB loop from ERK to RKIP should be included in the parameters of the FB 
loop of PI3K-Rac-Raf activation pathway. Finally, it has been reported that S6K and Akt 
phosphorylate Sin1 and, thereby, negatively regulate mTORC2 activity [39]. However, in 
our experimental condition, S6K activity sustains high level after EGF stimulation, 
indicating that the negative FB regulation to Sin1 does not play a major role in our cells 
(Fig. 7B, blue line). 
 In summary, we evaluated the quantitative contribution of FF and FB regulations 
  
in the Ras-ERK and PI3K-S6K pathways by combining high-throughput FRET imaging 
with chemical inhibitor perturbations. Notably, we found a novel negative FB regulation 
from RSK to Raf via TSC and Rheb. Although each reaction making up the FB loop was 
reported previously [9, 10], the role of a negative FB loop was revealed only by the ODE-
based modeling with quantitative parameters. Several issues remain to be addressed in 
future works. First, the kinetic parameters in the PI3K-S6K pathway should be measured 
experimentally to improve our mathematical model. Second, even after the fitting there 
remains substantial discrepancy between simulation and experimental data (Fig. 5). Our 
model has been developed by a bottom-up approach based on experimentally-determined 
parameters, and therefore it is reasonable that the model has not completely included 
reactions that are required for reproducing experimental data. Meanwhile, we could say that 
this discrepancy between simulation and experiments will provide a clue to predict hidden 
pathways or regulations. Nevertheless, the quantitative simulation model will have a 
potential advantage for predicting a rational combination of molecular targeting drugs in 
order to overcome their intrinsic resistance mediated by FF and FB regulations.  
 
 
Materials and Methods 
 
Reagents and plasmids 
Epidermal growth factor (EGF) was purchased from Sigma-Aldrich (St. Louis, MO). 
PD153035, PI-103 and LY294002 were obtained from Calbiochem (La Jolla, CA). 
PD184352 was obtained from Toronto Research Chemicals (Ontario, Canada). BI-D1870 
was purchased from Symansis (Shanghai, China). Torin1 was obtained from Tocris 
Bioscience (Bristol, UK). Blasticidin S and Puromycin were purchased from Invivogen 
(San Diego, CA). The FRET biosensors for EGFR (PicchuEV-pm), Ras (RaichuEV-Ras), 
ERK (EKAREV-nuc), JNK (JNKAREV), PKA (AKAR3EV) and S6K (Eevee-S6K) were 
developed previously [20, 40-42]. Vybrant DyeCycle Ruby was purchased from Invitrogen 
(San Diego, CA). 
 
Cell culture 
HeLa cells were purchased from the Human Science Research Resources Bank (Sennan-
shi, Japan). HeLa cells were maintained in DMEM (Sigma-Aldrich) supplemented with 
10% fetal bovine serum (FBS). Plasmids were transfected into HeLa cells by 293Fectin 
  
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Stable cell lines 
expressing FRET biosensors were established as described previously [43].  
 
Time-lapse FRET imaging 
FRET imaging were performed as described previously [43]. For multiplex imaging, HeLa 
cells stably expressing FRET biosensors were mixed and passaged into 8 wells of a 96-well 
glass base plate or 4-well glass-bottom dish. One day after seeding, the cells were serum 
starved for one day with the medium described above. The glass-bottom 96-well plate or 4-
well dish base plate was imaged by an inverted microscope as described earlier. The 
imaging interval was three minutes with 96-well glass base plate and one or two minutes 
with 4-well glass-bottom dish (Supplementary dataset 1). After the time-lapse imaging, the 
nuclei of the cells were stained by Vybrant DyeCycle Ruby and imaged. Using the nucleus-
stained images, the FRET images were processed and analyzed with a custom-made 
MATLAB program as described below. 
 
Image processing with a custom-made MATLAB program 
The custom-made image-processing program was developed with MATLAB software 
(version R2012a; The Mathworks Inc., Natick, MA). This program recognized cell nuclei 
from images of nuclei stained with Vybrant DyeCycle Ruby. To distinguish 3 cell lines 
mixed as described above, it executed an algorithm to classify them according to their 
fluorescent localization. Then, the FRET and CFP intensities were averaged over each cell 
area, and the FRET/CFP value was calculated. In some experiments, the FRET/CFP value 
from before 10 min to the time of stimulation was averaged and used as the reference. The 
ratio of the raw FRET/CFP value to the reference value was defined as the normalized 
FRET/CFP value. In the experiment in Fig. 8B, this program recognized cells from 
fluorescent images of EKAREV-nuc and counted the cell number. 
 
Numerical simulation of EKAREV-nuc 
Numerical simulation of EKAREV-nuc was performed by MATLAB software to convert 
the amount of phosphorylated ERK into FRET/CFP values in EKAREV-nuc 









Kinetic modeling and numerical simulation 
The Ras/ERK and Akt pathways simulation implemented here consists of 48 kinetic 
reactions involving 19 different molecules, 73 parameters and 4 inhibitor values. The 
kinetic reactions were based on Michaelis-Menten kinetics, but many reactions were 
described as the first-order kinetics when reactions could be approximated in order to 
decrease the number of parameters. The biochemical reactions and the parameters used in 
this study are shown in the Supporting Information (Table S1-S3). All kinetic reactions 
were described with mass action kinetics by using CellDesigner (version 4.1) [44] (Fig. 4). 
The ordinary differential equations with parameters were exported to the MATLAB 
software through a Systems Biology Workbench (version 2.8.1) [45]. Numerical simulation 
was performed by MATLAB software (Supplementary Codes). The reactions with 
inhibitors were expressed as follows. 




When the simulation was performed without inhibitors, the inhibitor value was set to 1. 
When inhibitors were introduced in the simulation, the inhibitor value was set from 0 to 1. 
The inhibition strength in Fig. 8 and Fig. 9 was converted to an inhibitor value according to 









where each constant is determined so as to reproduce the experimental result. 
 
Parameter fitting 
For the determination of kinetic parameters, unconstrained nonlinear optimization was 
implemented by MATLAB software using the fminsearch function. To compare the results 
of simulation and FRET imaging, FRET ratios were estimated by fractions of 
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Figure 1. Outline of FRET imaging, image processing, and kinetic simulation. HeLa 
cells stably expressing FRET biosensors for Ras (RaichuEV-Ras-pm), EGFR (PicchuEV-
pm), ERK (EKAREV-nls), JNK (JNKAREV-nls), S6K (Eevee-S6K-nes) and PKA 
(AKAR3EV-nes) were established. Three cell lines (grey rectangles) were mixed and 
seeded onto 96-well or 4-well glass-bottom dishes. The cells were stimulated with EGF and 
inhibitors, and imaged with an inverted epifluorescence microscope. The images were 
processed by a semi-automatic program to extract changes in molecular activity. Based on a 
large imaging data set and kinetic parameters, a kinetic simulation model was built and 
compared with experimental data. 
 
Figure 2. Sensitivity of PicchuEV-pm and EKAREV-nuc. (A and B) HeLa cells stably 
expressing PicchuEV-pm (A) and EKAREV-nuc (B) were serum starved and time lapse 
images were obtained. While FRET imaging, cells were stimulated with 50 ng/ml EGF and 
treated with 1 µM PD153035, an EGFR inhibitor (A) or 10 µM PD184352, a MEK 
inhibitor (B) at time points indicated in each graph. Dark lines represent the average value 
  
with areas reflecting the s.d. (n > 9). (C) HeLa cells stably expressing EKAREV-nuc were 
stimulated with various concentrations of TPA. The FRET/CFP values were quantified at 
30 min after TPA stimulation. Under the same condition, HeLa cells were lysed with SDS 
sample buffer and subjected to Phos-Tag Western blotting in order to quantify the fraction 
of phosphorylated ERK (pTpY-ERK). FRET/CFP values are plotted as a function of the 
fractions of pTpY-ERK (dots) and fitted by computer simulation (line). Of note, 
experimental data are reused from [46]. (D) Schematic of the simulation model of 
EKAREV-nuc used in (C). FRET/CFP value was calculated as described in Materials and 
Methods. 
 
Figure 3. Evidences of feedforward and feedback regulations in EGFR signaling. (A) 
Schematic of the negative feedback from ERK to EGFR. (B) EGFR activity upon 10 ng/ml 
EGF before or after inhibitor treatments (20 µM LY294002, a PI3K inhibitor; 10 µM 
PD184352, an MEK inhibitor; 1 µM PD153035, an EGFR inhibitor). The FRET/CFP 
values are normalized by the FRET/CFP value just before inhibitor treatment. (C) 
Schematic of the coherent feedforward regulation from Ras to Raf through PI3K and Rac1. 
(D) ERK activity in response to 10 ng/ml EGF, followed by the treatment with inhibitors at 
the indicated time points (10 µM PI-103, a PI3K inhibitor, 10 µM PD184352, and 1 µM 
PD153035). The FRET/CFP values are normalized by the FRET/CFP value just before 
inhibitor treatment. (E and F) The dominant negative mutant of Rac1(RacN17 (E)), and 
HRas (HRasN17 (F)), reduced 50 ng/ml EGF-induced ERK and S6K activation, 
respectively. (G) Schematic of the negative feedback from RSK to Raf through TSC and 
Rheb. (H and I) ERK (H) and S6K (I) activity upon inhibitors (1 µM Torin1, an 
mTORC1/2 inhibtor; 10 µM BI-D1870, a RSK inhibitor) and 10 ng/ml EGF treatment. (J) 
Rheb depletion by shRNA enhanced the ERK activation induced by 1 µM BI-D1870 
treatment. Dark lines represent the average value with areas reflecting the s.d. (n > 9). 
 
Figure 4. Overview of the kinetic simulation model of Ras-ERK and PI3K-S6K 
pathways. Diagram of the kinetic simulation model of the Ras-ERK and PI3K-S6K 
signaling network is depicted with gene mutations and molecular targeting drugs. All 
parameters and reactions are described in Table S1-3. 
 
Figure 5. Simulated ERK activities with experimental results. (A-D) ERK activity in 
response to 10 ng/ml EGF, followed by the treatment with mock (A) or inhibitors at the 
  
indicated time points. Circles represent averaged FRET/CFP values as in Fig. 3D (n > 9). 
The FRET/CFP values are normalized by the FRET/CFP value just before inhibitor 
treatment. Solid lines demonstrate reconstituted FRET/CFP values from simulated active 
ERK value according to the model shown in Fig. 2C and 2D. (E) EGF-induced ERK 
activation with or without Rac1 dominant negative mutant (Rac1N17). Circles represent 
averaged FRET/CFP values as in Fig. 3E (n > 9). (F) ERK activity upon inhibitors (10 µM 
BI-D1870, a RSK inhibitor) and 10 ng/ml EGF treatment. Circles represent averaged 
FRET/CFP values as in Fig. 3H (n > 9). 
 
Figure 6. Kinetic simulation of Ras-ERK and PI3K-S6K signaling including 
feedforward and feedback regulations. (A) Schematic representation of EGFR signaling 
including Ras-ERK and PI3K-S6K pathways. (B) Numerical simulation of EGFR (left) and 
ERK (right) activity in response to EGF and the indicated inhibitors. (C and D) Rac1 (C) 
and Ras (D) inhibition markedly reduced the ERK and S6K activation stimulated by EGF, 
respectively. (E) Simulation of ERK (left) and S6K (right) activity in response to the 
indicated inhibitors and EGF. (F) Rheb inhibition enhanced the ERK activation induced by 
an RSK inhibitor.  
 
Figure 7. Coordinated roles of feedforward and feedback regulations. (A) Simulation 
of S6K activity upon EGF followed by inhibitor treatment. (B) S6K activity upon 50 ng/ml 
EGF followed by inhibitor treatment (20 µM LY294002, 10 µM PD184352, and 1 µM 
PD153035). (C and D) Pretreatment with an RSK inhibitor reduced the EGF-induced ERK 
activation in both the simulation (C) and experiments (D), in which cells were treated with 
10 µM BI-D1870, followed by stimulation with 1 ng/ml EGF. (E) Simulation of ERK 
activation induced by EGF under the condition that the indicated feedforward or feedback 
regulations are impaired. Dark lines represent the average value with areas reflecting the 
s.d. (n > 9). (F) Schematic of the roles of feedforward and feedback regulations in a manner 
dependent on the temporal phase of EGF stimulation.  
 
Figure 8. Evaluation of the effect of molecular targeting drugs on cytotoxicity in 
KRas- or BRaf-mutated cells. (A) Pharmacological profiling data obtained from the 
Cancer Cell Line Encyclopedia. The average dose-responses of cancer cell lines against a 
BRaf inhibitor, PLX-4720, and an MEK inhibitor, AZD6244, are shown. The numbers of 
cell lines are as follows: KRas mutant, n = 82; BRaf mutant, n = 50. (B) HCT-116 cells and 
  
HT-29 cells were treated with PI-103 in the absence (left) or presence (right) of AZD6244. 
Three days after treatment, the cell number was quantified. Equal concentrations of both 
AZD6244 and PI-103 were administered in the concomitant treatment. The average values 
of 5 experiments are shown. Error bars indicate the S.D. (C) The sums of the absolute 
values of pERK and pAkt under the conditions of BRaf inhibition (left), MEK inhibition 
(middle left), PI3K inhibition (middle right) and concomitant inhibition of both MEK and 
PI3K (right) were numerically calculated, and normalized at non-inhibition condition in 
KRas- or BRaf-mutated cells. MEK and PI3K were equally inhibited under the concomitant 
inhibition of MEK and PI3K (right).  
 
Figure 9. Relation between feedforward/feedback regulations and differential effects 
of molecular targeting drugs on mutant cells. (A and B) Dose response of ERK (left) and 
Akt (right) phosphorylation to MEK inhibition (cyan), BRaf inhibition (orange), PI3K 
inhibition (green) and concomitant inhibition of both MEK and PI3K (magenta) in KRas-
mutated (A) and BRaf-mutated (B) cells. (C) Proposed model of the differential effects of 
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